BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17503223)

  • 1. HSP-70 as a nonspecific early marker in cisplatin ototoxicity.
    Ramírez-Camacho R; Citores MJ; Trinidad A; Verdaguer JM; García-Berrocal JR; Marero AM; Puente A; González-García JA; Vargas JA
    Acta Otolaryngol; 2007 Jun; 127(6):564-7. PubMed ID: 17503223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heat shock protein 70 and cellular disturbances in cochlear cisplatin ototoxicity model.
    García-Berrocal JR; Nevado J; González-García JA; Sánchez-Rodríguez C; Sanz R; Trinidad A; España P; Citores MJ; Ramírez-Camacho R
    J Laryngol Otol; 2010 Jun; 124(6):599-609. PubMed ID: 20307356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin-induced hearing loss does not correlate with intracellular platinum concentration.
    Ramírez-Camacho R; Fernández DE; Verdaguer JM; Gómez MM; Trinidad A; García-Berrocal JR; Corvillo MA
    Acta Otolaryngol; 2008 May; 128(5):505-9. PubMed ID: 18421602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of N-acetylcysteine on carboplatin-induced ototoxicity and nitric oxide levels in a rat model.
    Okur E; Kilinc M; Yildirim I; Kilic MA; Tolun FI
    Laryngoscope; 2007 Dec; 117(12):2183-6. PubMed ID: 17909450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ginkgo biloba extract (EGb 761) protects against cisplatin-induced ototoxicity in rats.
    Huang X; Whitworth CA; Rybak LP
    Otol Neurotol; 2007 Sep; 28(6):828-33. PubMed ID: 17450108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin alleviates cisplatin-induced ototoxicity in vivo.
    Fang B; Xiao H
    Biochem Biophys Res Commun; 2014 Jun; 448(4):443-7. PubMed ID: 24796670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV-mediated delivery of the caspase inhibitor XIAP protects against cisplatin ototoxicity.
    Cooper LB; Chan DK; Roediger FC; Shaffer BR; Fraser JF; Musatov S; Selesnick SH; Kaplitt MG
    Otol Neurotol; 2006 Jun; 27(4):484-90. PubMed ID: 16791039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin ototoxicity to the rat inner ear: a role for HMG1 and iNOS.
    Li G; Liu W; Frenz D
    Neurotoxicology; 2006 Jan; 27(1):22-30. PubMed ID: 16125245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of increased activities of Na+, K+-ATPase and Ca2+-ATPase with the reversal of cisplatin ototoxicity induced by D-methionine in guinea pigs.
    Cheng PW; Liu SH; Hsu CJ; Lin-Shiau SY
    Hear Res; 2005 Jul; 205(1-2):102-9. PubMed ID: 15953519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig.
    Ekborn A; Lindberg A; Laurell G; Wallin I; Eksborg S; Ehrsson H
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):36-42. PubMed ID: 12497204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhalation of hydrogen gas attenuates cisplatin-induced ototoxicity via reducing oxidative stress.
    Qu J; Li X; Wang J; Mi W; Xie K; Qiu J
    Int J Pediatr Otorhinolaryngol; 2012 Jan; 76(1):111-5. PubMed ID: 22055279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery of hearing following cisplatin ototoxicity in the guinea pig.
    O'Leary SJ; Klis SF
    Anticancer Res; 2002; 22(3):1525-8. PubMed ID: 12168832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of heat shock protein 72 in rat cochlea with cisplatin-induced acute ototoxicity.
    Oh SH; Yu WS; Song BH; Lim D; Koo JW; Chang SO; Kim CS
    Acta Otolaryngol; 2000 Mar; 120(2):146-50. PubMed ID: 11603760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study on the ototoxicity of cisplatin with distortion products].
    Orts Alborch M; García Callejo J; Morant Ventura A; Ferrer Baixauli F; Esparcia Navarro M; Marco Algarra J
    Acta Otorrinolaringol Esp; 2000; 51(6):469-77. PubMed ID: 11142781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supporting cells as a target of cisplatin-induced inner ear damage: therapeutic implications.
    Ramírez-Camacho R; García-Berrocal JR; Buján J; Martín-Marero A; Trinidad A
    Laryngoscope; 2004 Mar; 114(3):533-7. PubMed ID: 15091230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin-induced ototoxicity: transporters playing a role in cisplatin toxicity.
    Waissbluth S; Daniel SJ
    Hear Res; 2013 May; 299():37-45. PubMed ID: 23467171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study.
    van Ruijven MW; de Groot JC; Klis SF; Smoorenburg GF
    Hear Res; 2005 Jul; 205(1-2):241-8. PubMed ID: 15953532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
    J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteopontin does not mitigate cisplatin ototoxicity or nephrotoxicity in adult mice.
    Schmitt NC; Rubel EW
    Otolaryngol Head Neck Surg; 2013 Oct; 149(4):614-20. PubMed ID: 23884286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of cisplatin ototoxicity and progress in otoprotection.
    Rybak LP
    Curr Opin Otolaryngol Head Neck Surg; 2007 Oct; 15(5):364-9. PubMed ID: 17823555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.